These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35338693)

  • 1. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.
    Díaz C; González-Olmedo C; Díaz-Beltrán L; Camacho J; Mena García P; Martín-Blázquez A; Fernández-Navarro M; Ortega-Granados AL; Gálvez-Montosa F; Marchal JA; Vicente F; Pérez Del Palacio J; Sánchez-Rovira P
    Mol Oncol; 2022 Jul; 16(14):2658-2671. PubMed ID: 35338693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
    Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
    Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer.
    Yang K; Zhang F; Han P; Wang ZZ; Deng K; Zhang YY; Zhao WW; Song W; Cai YQ; Li K; Cui BB; Zhu ZJ
    Metabolomics; 2018 Aug; 14(9):110. PubMed ID: 30830371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients.
    Hou Y; Yin M; Sun F; Zhang T; Zhou X; Li H; Zheng J; Chen X; Li C; Ning X; Lou G; Li K
    Mol Biosyst; 2014 Aug; 10(8):2126-33. PubMed ID: 24865370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of neoadjuvant systemic therapies in breast cancer in Australia and New Zealand: Breast Surgeons of Australia and New Zealand quality audit.
    Duffield JA; Blanch AJ; Esterman A; Bochner MA
    ANZ J Surg; 2023 Apr; 93(4):889-895. PubMed ID: 36912120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [No Abstract]   [Full Text] [Related]  

  • 11. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Metabolome Signatures to Predict Responsiveness to Neoadjuvant Chemotherapy in Breast Cancer.
    Silva AAR; Cardoso MR; Oliveira DC; Godoy P; Talarico MCR; Gutiérrez JM; Rodrigues Peres RM; de Carvalho LM; Miyaguti NADS; Sarian LO; Tata A; Derchain SFM; Porcari AM
    Cancers (Basel); 2024 Jul; 16(13):. PubMed ID: 39001535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
    Yamada M; Jinno H; Naruse S; Isono Y; Maeda Y; Sato A; Matsumoto A; Ikeda T; Sugimoto M
    Breast Cancer Res Treat; 2024 Sep; 207(2):393-404. PubMed ID: 38740665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
    Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
    Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.